CAS: 208720-71-2; (3R,4R,5S)-Methyl 4-Acetamido-5-Amino-3-(Pentan-3-Yloxy)Cyclohex-1-Enecarboxylate

上下游产品

methanol oseltamivir (1R,5R,6R)-5-Methoxymethoxy-7-aza-bicyclo[4.1.0]hept-3-ene-3-carboxylic acid methyl ester (3R,4R,5S)-4-Acetylamino-5-azido-3-methoxymethoxy-cyclohex-1-enecarboxylic acid methyl ester

📜(3R,4S,5R)-5-Azido-4-Methanesulfonyloxy-3-Methoxymethoxy-Cyclohex-1-Enecarboxylic Acid Methyl Ester置于盐酸,Sodium Azide,三氟化硼乙醚,氯化铵,三乙胺,三苯基膦体系中,用 四氢呋喃,甲醇,水,N,N-二甲基甲酰胺 用作溶剂,化学反应 93.75H,反应生成奥塞米韦酸甲酯
参考文献:新颖化合物,其合成方法及治疗用途
标题:新颖化合物,其合成方法及治疗用途
摘要:公开了新颖化合物.这些化合物一般包含有酸性基团,碱性基团,取代的氨基或n-酰基和具有选择性羟基化的烷基部分的基团.还公开了包含本发明的抑制剂的医药组合物.还公开了在可能含有神经氨酸苷酶的试样中抑制神经氨酸苷酶的方法.还公开了带标记的本发明化合物的抗原材料,聚合物,抗体,共轭物及检测神经氨酸苷酶活性的测定方法.

专利信息

专利号:US-8304553-B2
优先权日:2007-12-19
标题:Method of forming oseltamivir and derivatives thereof
发明人：LIU XUEWEI; MA JIMEI
权利人:LIU XUEWEI; MA JIMEI; UNIV NANYANG TECH
摘要:A process is provided for the synthesis of 4,5-diamino cyclohexene carboxylate ester (1): or a pharmaceutically acceptable salt thereof. R 1 -R 3 are a silyl-, an aliphatic, alicyclic, aromatic, arylaliphatic, or an arylalicyclic group. R 4 , R 11 and R 12 are H, a silyl-group, an aliphatic, alicyclic, aromatic, arylaliphatic, or an arylalicyclic group. 3,4-Dihydropyran compound (9): with R 5 and R 6 being suitable protecting groups, is reacted to form aldehyde (4): which is oxidized and converted to N-substituted carbamate (3): with R 7 being a suitable protecting group. (3) is, via oxazolinidone (13): converted to azido carboxylate ester (2): and then to 4,5-diamino cyclohexene carboxylate ester (1).

专利号:US-2004053999-A1
优先权日:1997-09-17
标题 :Novel compounds and methods for synthesis and therapy
发明人：BISCHOFBERGER NORBERT W; DAHL TERRENCE C; HITCHCOCK MICHAEL J M; KIM CHOUNG U; LEW WILLARD; LIU HONGTAO; MILLS ROGER G; WILLIAMS MATTHEW A
摘要:Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.